// App-Quantinova.ai

8010 : Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Efficacy and Safety Analysis

Researchers

Presenter

  • Maria-Victoria Mateos

Principal Investigators

  • Robert Z. Orlowski

  • David Samuel DiCapua Siegel

  • Donna Ellen Reece

  • Philippe Moreau

  • Enrique M. Ocio

  • Jatin J. Shah

  • Paula Rodriguez-Otero

  • Nikhil C. Munshi

  • David Avigan

  • Joy Yang Ge

  • Patricia Maria Marinello

  • Jesus San Miguel

Medical Centers

  • University Hospital of Salamanca, Salamanca, Spain

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • John Theurer Cancer Centre, Hackensack University Medical Center, Hackensack, NJ

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • University Hospital Hotel-Dieu, Nantes, France

  • Clinica Universidad de Navarra, Pamplona, Spain

  • Dana-Farber Cancer Institute, Boston, MA

  • Beth Israel Deaconess Medical Center, Boston, MA

  • Merck & Co., Inc., Kenilworth, NJ

  • University of Navarra, Pamplona, Spain

Locations

  • United States

  • Spain

  • France

  • Canada

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pembrolizumab

  • Lenalidomide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT02036502

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved